President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

As a patient ... For Novo Nordisk, the site is clearly about supporting greater access to their medicines in the US and Puerto Rico, and in particular to support their financial assistance programme.

President-elect Donald Trump has not backed down from insisting that the United States needs to acquire Greenland, a Danish ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is ...

During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ... enough for prolonged patient treatment to obtain ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.